跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 340 条关于
“PIK3CA H1047R”
全部
340
临床试验
173
药物
29
机构
0
资讯
138
上个月
Recursion Pharmaceuticals Advances First AI-Discovered Neuroscience Target with Genentech, Lowers Cash Burn Guidance
去年
Inavolisib Demonstrates Promising Disease Control in PIK3CA-Mutated Solid Tumors
7个月前
OnKure Faces Critical Data Readout for H1047R-Specific PI3Kα Inhibitor as Competition Intensifies
去年
Capivasertib Plus Fulvestrant Shows Promise in PIK3CA-Altered Metastatic Breast Cancer
5年前
Inavolisib Combination Significantly Improves Survival in PIK3CA-Mutant Advanced Breast Cancer
2年前
Inavolisib Shows Promise in PIK3CA-Mutated Advanced Solid Tumors
去年
Capivasertib Shows Promise in ER+/HER2- Metastatic Breast Cancer with PIK3CA Mutations
去年
RLY-2608 Shows Promise in PIK3CA-Mutant Breast Cancer with Improved Tolerability Profile
去年
Inavolisib Regimen Significantly Improves Survival in PIK3CA-Mutated Breast Cancer
去年
Alpelisib Plus Fulvestrant Shows Promise in Advanced Breast Cancer With PIK3CA Mutation
第 1 页,共 14 页
上一页
下一页